Printer Friendly

Syros Pharmaceuticals to present preclinical data on CDK7 inhibitors at AACR.

Syros Pharmaceuticals announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American Association for Cancer Research Annual Meeting taking place March 29-April 3 in Atlanta. The presentation on SY-1365 will highlight data showing that alterations in the RB pathway are predictive of response to SY-1365 in patient-derived xenograft models of high-grade serous ovarian cancer, supporting exploration of RB alterations as potential biomarkers of response to SY-1365. The presentation on SY-5609 will describe in vitro and in vivo data on the selectivity, potency and anti-tumor activity of SY-5609 that supported its advancement into investigational new drug application ND-enabling preclinical studies.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Feb 27, 2019
Previous Article:Whitestone REIT reports Q4 FFO 23c, consensus 29c.
Next Article:Guardant Health reports results from NILE study.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters